Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
36 results about "Oncotic pressure" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Oncotic pressure, or colloid osmotic pressure, is a form of osmotic pressure induced by proteins, notably albumin, in a blood vessel's plasma (blood/liquid) that displaces water molecules, thus creating a relative water molecule deficit with water molecules moving back into the circulatory system within the lower pressure venous end of capillaries. It has the opposing effect of both hydrostatic blood pressure pushing water and small molecules out of the blood into the interstitial spaces within the arterial end of capillaries and interstitial colloidal osmotic pressure. These interacting factors determine the partition balancing of total body extracellular water between the blood plasma and the larger extracellular water volume outside the blood stream.
Peritoneal Dialysis Methods and Apparatus
ActiveUS20100217181A1Increase percentageImprove wear resistancePeritoneal dialysisProtein compositionPeritoneal fluid
A peritoneal-based (“bloodless”) artificial kidney processes peritoneal fluid without need for additional fluids (“waterless”). Fluid is separated into a protein-rich stream and a protein-free stream. The protein-rich stream is regenerated using a sorbent assembly, and its protein composition can be modified by removal of selected protein(s) (“dialysate-pheresis”). It is then reconstituted with additives and returned into the peritoneal cavity, thereby reducing protein-loss and providing oncotic-pressure for ultrafiltration. The protein-free stream is used to produce free water, and an alkaline or acid fluid for optimization of the composition of the regenerated stream. The unused protein-free stream can be used to “reverse flush” the separator to maintain its patency and the excess discarded for fluid-balance regulation. Compared to prior art, immobilization of urease allows more protein rich fluid to be regenerated and re-circulated into the peritoneal cavity for toxin removal and allows practicable development of portable and wearable artificial kidneys.
Owner:RGT UNIV OF CALIFORNIA +1
Composition and method to prevent and treat brain and spinal cord injuries
A composition and method for treating and preventing injury to central nervous system tissue are provided. The composition is comprised of agents that can increase colloidal osmotic pressure and osmolality. The method comprise of: a). Withdrawing cerebrospinal fluid from the subarachnoid spaces around the tissue to be treated or protected and b). Injecting the composition into subarachnoid spaces.
Owner:WANG YANMING
Pharmaceutical composition containing artificial oxygen carrier
InactiveUS7417118B2High oxygen carrying efficiencyBiocideOrganic active ingredientsAntioxidantPorphyrin
A pharmaceutical composition containing an artificial oxygen carrier, which has high oxygen carrying efficiency; and has a required colloid osmotic pressure, an appropriate crystalloid osmotic pressure, pH, and electrolyte balance. The composition is prepared by appropriately adding at least one substance selected from the group consisting of a compound capable of providing a colloid osmotic pressure, an electrolyte, a saccharide, an amino acid, an antioxidant, a pH adjuster, and an isotonizing agent to a preparation including a liposome-encapsulated hemoglobin in which a hemoglobin is encapsulated in a liposome or to a preparation including a conjugate of a porphyrin-iron complex and albumin.
Owner:NIPRO CORP
Method for preparing decellularized cornea
ActiveCN106421908ALow transparencyAvoid breedingTissue regenerationProsthesisCell-Extracellular MatrixECM Protein
The invention provides a method for preparing decellularized cornea. Due to the selection of components and proportions, colloid osmotic pressure of a decellularized cornea preparation liquid can be maintained by using a prepared protection liquid, and compared with a conventional decellularized cornea preparation liquid, the decellularized cornea preparation liquid is capable of remarkably alleviating the situation that the cornea transparency is degraded as an extracellular matrix such as collagen is excessively swelled and lost in the later cell treatment process; in addition, due to the addition of antibiotics such as tobramycin, bacterium propagation of susceptible cornea can be inhibited, and the contamination rate in the treatment process can be reduced. By adopting the method provided by the invention, cells can be crushed, and the situation that the trenchancy is degraded as cornea matrix collagen is damaged by long-term high pressure can be avoided. Secondly, as a detergent and nuclease act up simultaneously, cell debris and nucleic acid components can be relatively rapidly and effectively removed, and the situation that the trenchancy of the cornea is degraded as protein components such as cornea collagen are damaged in long-term treatment of the detergent and other components can be avoided.
Owner:SHENZHEN AINEAR CORNEA ENG
Method for preparing narrow-distribution low average molecular weight polymerized hemoglobin
InactiveCN101200499AEasy to separateOvercome the defect of poor uniformityHaemoglobins/myoglobinsPeptide preparation methodsOncotic pressureColloid
A preparation method of narrow-distribution polymerized hemoglobin with low average molecular weight is characterized in that the method includes the following steps: {1} the hemoglobin is added into the gel retardation spectrum for balance through a pump and then distributively added with double-function crosslinker for polyreaction; {2} buffer solution is used to elute and collect the polymer produced in the step {1}, amide acid is used in the collected solution for stopped reaction and then hyperfiltration and concentration are carried out; {3} the obtained polymerized hemoglobin is treated by reduction by sodium borohydride and then is separated and purified through hyperfiltration and chromatography. The advantages of the present invention are that 1. the polymerized hemoglobin prepared by the present invention is narrow-distribution polymerized hemoglobin with low average molecular weight less than 200kD; 2. the present invention overcomes the poor homogeneity of the polymer in the traditional glutaraldehyde preparation method; 3. the polymerized hemoglobin is easily separated from the unpolymerized single hemoglobin and the reduced number of protein colloid decreases the osmotic pressure without any obvious change in viscosity.
Owner:天津协和生物科技发展有限公司
Method, device and fluid for treatment of a heart after harvesting
InactiveUS20120183945A1Mitigate, alleviate or eliminate onePharmaceutical containersMedical packagingOncotic pressurePotassium
Method and device for treatment of a heart after harvesting and before transplantation. The device includes a container intended to comprise the heart; a first line for connection to an aorta of the heart; a fluid circuit comprising an oxygenator for oxygenating said fluid and a heater / cooler for regulating the temperature of said fluid; and a pump for perfusion of said fluid through the coronary blood vessels of the heart. The fluid includes an oncotic agent exerting an oncotic pressure larger than about 30 mmHg; and is cardioplegic by comprising a potassium concentration, which is between 15 mM and 30 mM. A control device is arranged for controlling the pump to perform said perfusion intermittently, whereby the perfusion time is less than half of the cycle time. The perfusion is performed at a pressure, which is at least 15 mmHg and at least 15 mmHg lower than said oncotic pressure.
Owner:XVIVO PERFUSION
Use of tetrahydropyridines in preparing medicine for treating hepatitis or hepatocirrhosis
InactiveCN101491527AControl disease progressionIncrease RNA contentOrganic active ingredientsDigestive systemDiseaseProfibrinolysin
The invention discloses novel application for Ectoine, namely application of the Ectoine in preparing medicines of treating hepatitis or hepatocirrhosis. The effective dosage range of the Ectoine is 0.1 to 100 mg / kg of body weight, preferably 8 to 50mg / kg of the body weight. When in use, the Ectoine adopts a mode of intravenous infusion. The experiment implemented by the inventor proves that the Ectoine can protect hepatic tissue, and inhibit the reduction of albumin, other proteins, amino acid, thrombozyme and profibrinolysin in liver and serum when the hepatitis and the hepatocirrhosis develop, thereby maintaining normal colloid osmotic pressure, delaying the generation of ascites, improving the content of RNA in the liver and achieving the aims of protecting the liver and controlling the growth of the disease of the hepatitis and the hepatocirrhosis. The Ectoine can be used for assisting treatment of the hepatitis and the hepatocirrhosis.
Owner:济南环肽医药科技有限公司
NK cell low-temperature preservation re-infusion liquid
InactiveCN111838137AReduce oxidative damageInhibition formationDead animal preservationVitamin CTissue repair
The invention provides an NK cell low-temperature preservation re-infusion liquid. According to the invention, a glucose and sodium chloride injection is added into the NK cell low-temperature preservation re-infusion liquid to serve as a diluent / buffer liquid, so that the effects of maintaining the pH value, the ion osmotic pressure and the colloid osmotic pressure and providing energy glucose for cells are achieved; the added human serum albumin can maintain the constant osmotic pressure of plasma colloid and supply nutrition; the added vitamin C can promote antibody and collagen formation and tissue repair, and meanwhile, the vitamin C also has the effects of resisting oxidation, resisting free radicals and inhibiting tyrosinase formation, so that the oxidative damage of cells can be reduced, and the accumulation of peroxides in the cells can be quickly relieved. According to the NK cell low-temperature preservation re-infusion liquid, the survival rate of NK cells can be kept at 80% or above after the NK cells are preserved for 48 h at the temperature of 4 DEG C, and a preparation can be directly re-infused.
Owner:SHENZHEN PREGENE BIOPHARMA CO LTD
Drug composition for treating encephaledema by taking intracellular osmotic pressure as target
ActiveCN108653305AVolume stabilityConvenient treatmentNervous disorderBlood disorderNimodipineCantharidin
The invention relates to a drug composition for treating encephaledema and a preparation method of the drug composition. The compound drug composition comprises the following active ingredients: sennoside A, cantharidin or a derivative of cantharidin, nimodipine or nifedipine, cinepazide maleate and edaravone. An active drug and a drug combination capable of reducing colloid osmotic pressure and crystal osmotic pressure in brain cells so as to treat the encephaledema are looked for through a cell experiment, and a novel pharmaceutical application is provided clinically.
Owner:NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Cornea metaphase preserving fluid without serum component
The invention relates to cornea metaphase preserving fluid without a serum component. The cornea metaphase preserving fluid is prepared from an compound electrocular irrigating solution, sodium chloride, magnesium sulfate, monopotassium phosphate, chondroitin sulfate, sodium hyaluronate, a HEPES buffer solution, hydrochloric acid dexamethasone, reduced glutathione and levofloxacin. The cornea metaphase preserving fluid is reddish and transparent liquid with a specific electrolyte ionic concentration, a pH value, crystalloid osmotic pressure and colloid osmotic pressure. Needed raw materials are easy to get, the cornea metaphase preserving fluid does not contain the serum component, the risks of infecting special viruses is avoided, osmotic pressure of intracellular fluid and osmotic pressure of extracellular fluid are balanced through various ions, and the preservation effect is remarkable.
Owner:拜欧迪赛尔成都生物科技有限公司
Protection solution for preparing decellularized corneas
ActiveCN106212442ALow transparencyAvoid breedingDead animal preservationCell-Extracellular MatrixAdditive ingredient
The invention provides a protection solution for preparing decellularized corneas. The protection solution is a PBS or HBSS buffer solution, wherein 5-12 g / L of hyaluronic acid, 5-20 g / L of chondroitin sulfate, and 3-10 g / L of low molecular weight dextran are added in the PBS or HBSS buffer solution. According to the protection solution, protective ingredients are added in the basic buffer solution, the prepared protection solution can maintain the colloid osmotic pressure of a preparing solution of decellularized corneas through selection of components and a proportion, and compared with a traditional preparing solution for decellularized corneas, cornea transparency decreasing caused by excessive swelling and missing of extracellular matrix ingredients such as collagen in the decellularization treatment process in a later stage can be remarkably relieved; besides, antibiotic ingredients such as tobramycin are added, breeding of bacteria such as pseudomonas aeruginosa, klebsiella biofilm, enterobacter and proteus which are likely to infect corneas is suppressed, and the contamination probability in the treatment process is avoided.
Owner:SHENZHEN AINEAR CORNEA ENG
Use of recombinant gelatin-like proteins as plasma expanders and compositions suitable for plasma substitution
InactiveUS20050101531A1Reduced clearance rateLow clearance rateConnective tissue peptidesSugar derivativesHydroxyprolineClearance rate
The invention relates to compositions suitable for plasma substitution comprising as a plasma expander a recombinant gelatin-like protein. Characteristic is that the gelatin-like protein can be a monomer or a polymer like a dimer, trimer or a tetramer of a human recombinant gelatin-like protein having an isolectric point of less than 8. The resulting gelatin-like proteins provide a method to control the clearance rate of a plasma expander by its molecular weight. Preferably the gelatin-like proteins have a low hydroxyproline content which prevents the composition from gelling and thus allows the use of high-molecular weight proteins in order to establish a suitable colloid osmotic pressure. An additional advantage of the gelatin-like proteins is that these avoid the risk of anaphylactic shock that exists in conjunction with the use of commercially available preparations.
Owner:FUJIFILM MFG EURO
Process for preparing uniform molecule weight polymerized hemoglobin
InactiveCN1420127AEasy to separateOvercome the defect of inhomogeneityHaemoglobins/myoglobinsOncotic pressureColloid
A process for preparing the poly-haematoglobin with homogeneous molecular weight includes adsorbing haematoglobin by solid phase, adding dual-function reagent, polymerizing reaction, eluting and collecting the polymer by buffering liquid, and chromatography for separating and purifying the polyhaematoglobin. Its advantages are homogeneous molecular weight (about 135 thosands Dol), easy separation, and lower osmotic pressure.
Owner:INST OF PROCESS ENG CHINESE ACAD OF SCI
Method and apparatus for partial desalination of a concentrated salt solution
ActiveUS8119005B1Effective recoveryGeneral water supply conservationSeawater treatmentOncotic pressureDesalination
A desalination system and method are based on the biological mechanism occurring in the mammalian kidney which utilizes colloid osmotic pressure and hydrostatic pressure to recover diluted salt solution from a concentrated one. The desalination system includes fluidly connected chamber compartments, one of which is filled with a charged substance, for example, a charged colloid polymer, to form a colloid salt solution when filled with the concentrated salt solution. Peripheral chamber compartments are filled with the concentrated salt solution. A system of semi-permeable membranes, not permeable to the charged substance, separate the chambers one from another. The system operates in the filling, equilibration, dilute, and collecting cycles which are controlled by opening and closing of the semi-permeable membranes. Desalination is based on the transfer of water due to osmotic pressure gradient across the membranes and is driven by hydrostatic pressure, thus providing energy efficient process. The charged substance is not consumed during the desalination and may be repeatedly used.
Owner:WILHIDE REGINA
Use of tetrahydropyridines in preparing medicine for treating hepatitis or hepatocirrhosis
InactiveCN101491527BControl disease progressionIncrease RNA contentOrganic active ingredientsDigestive systemProfibrinolysinDisease
The invention discloses novel application for Ectoine, namely application of the Ectoine in preparing medicines of treating hepatitis or hepatocirrhosis. The effective dosage range of the Ectoine is 0.1 to 100 mg / kg of body weight, preferably 8 to 50mg / kg of the body weight. When in use, the Ectoine adopts a mode of intravenous infusion. The experiment implemented by the inventor proves that the Ectoine can protect hepatic tissue, and inhibit the reduction of albumin, other proteins, amino acid, thrombozyme and profibrinolysin in liver and serum when the hepatitis and the hepatocirrhosis develop, thereby maintaining normal colloid osmotic pressure, delaying the generation of ascites, improving the content of RNA in the liver and achieving the aims of protecting the liver and controlling the growth of the disease of the hepatitis and the hepatocirrhosis. The Ectoine can be used for assisting treatment of the hepatitis and the hepatocirrhosis.
Owner:济南环肽医药科技有限公司
Priming solutions for cardiopulmonary bypass
ActiveUS20130316977A1Low mean arterial pressureLow systemic vascular resistanceOrganic active ingredientsBiocideExtracorporeal circulationCardiopulmonary bypass
The present invention relates to priming solutions used during cardiopulmonary bypass procedures. In particular, the present invention relates to a cardiopulmonary bypass priming solution comprising a balanced salt solution and a combination of oncotic and non-oncotic dextran molecules. The present invention also relates to the use of the priming solution in a cardiopulmonary bypass method, a method of maintaining oncotic pressure in a patient during a cardiopulmonary bypass procedure, and a combination of cardiopulmonary bypass priming solution and cardiopulmonary bypass apparatus.
Owner:XVIVO PERFUSION
Application of colloidal gold to preparation of artificial cerebrospinal fluid reagent
ActiveCN108310008AIn line with physiological characteristicsWith osmotic pressureOrganic active ingredientsHeavy metal active ingredientsCrystallographyOncotic pressure
The invention provides new application of colloidal gold to preparation of an artificial cerebrospinal fluid reagent. The colloidal gold comprises colloidal gold particles, wherein the particle size range is 5 to 25 [mu]m, the average particle size is 13.4+ / -3.6 [mu]m, the colloidal gold concentration is 150 to 400 mg / L, and the average concentration is 232.4+ / -38.3 mg / L. The colloid osmotic pressure and the cell environment of human cerebrospinal fluid can be simulated, and novel artificial cerebrospinal fluid according with the physiological characteristics is created.
Owner:THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV
Optimized anti-oxidative accellular protective solution
The invention relates to an optimized anti-oxidative accelular protective solution, which has a critical effect on protection of structural completeness and biological nature of acellular tissues in the whole course of the decellularizing process. The protective solution is prepared from DMEM cellular culture medium L-histidine hydrochloride, allopurinol, chondroitin sulfate, low molecular dextran, hydroxypropyl methyl cellulose, HEPES buffer solution, dexamethason hydrochloride, reduced glutathione and levofloxacin. The protective solution is a light-red liquid with specific pH value, specific crystal and colloid osmotic pressure. The optimized anti-oxidative accelular protective solution is easily available in raw materials and economical in price, has strong applicability, wide application range and excellent anti-oxidation performance, and has a protective effect in the process of decellularizing biological tissues.
Owner:拜欧迪赛尔成都生物科技有限公司
Method, device and fluid for treatment of a heart after harvesting
InactiveUS20160309707A1Mitigate, alleviate or eliminate onePharmaceutical containersMedical packagingOncotic pressurePotassium
Method and device for treatment of a heart after harvesting and before transplantation. The device comprises a container intended to comprise the heart; a first line for connection to an aorta of the heart; a fluid circuit comprising an oxygenator for oxygenating said fluid and a heater / cooler for regulating the temperature of said fluid; and a pump for perfusion of said fluid through the coronary blood vessels of the heart. The fluid comprises an oncotic agent exerting an oncotic pressure larger than about 30 mmHg and is cardioplegic by comprising a potassium concentration between 15 mM and 30 mM. A control device is arranged for controlling the pump to perform said perfusion intermittently, whereby the perfusion time is less than half of the cycle time. The perfusion is performed at a pressure of at least 15 mmHg and at least 15 mmHg lower than said oncotic pressure.
Owner:XVIVO PERFUSION
Construction and application of optical detection method of biological macromolecules related to intracellular colloid osmotic pressure and related drug screening method
ActiveCN108548798BParticle size analysisColor/spectral properties measurementsProtein markersProtein labeling
Owner:NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Cryopreservation liquid and cryopreservation method for long-term preservation of stem cells and stem cell products
PendingCN114766471AReduce usageProlong the freezing timeDead animal preservationHydroxyethyl starchAmino Acid Injection
The invention discloses a cryopreservation solution and a cryopreservation method for long-term preservation of stem cells and stem cell products. The cryopreservation liquid is prepared from the following raw materials in parts by weight: 10 to 15 parts of low-molecular dextran, 2 to 8 parts of hydroxyethyl starch, 10 to 15 parts of chitosan, 3 to 6 parts of glycerol, 3 to 6 parts of dimethyl sulfoxide, 20 to 30 parts of glucose injection, 10 to 15 parts of compound amino acid injection and 20 to 30 parts of compound electrolyte injection. Under the combined action of the low-molecular dextran, the hydroxyethyl starch, the glucose injection, the compound amino acid injection and the compound electrolyte injection, the system balance of ion osmotic pressure and colloid osmotic pressure is maintained, an environmental condition beneficial to the survival of the stem cells is formed, and the long-term preservation of the stem cells is facilitated.
Owner:宁波建顺生物科技有限公司
Recombinant gelatin-like proteins for use as plasma expanders
InactiveUS7459431B2Reduce generationOrganic active ingredientsPeptide/protein ingredientsPlasma expanderHydroxyproline
The invention relates to compositions suitable for plasma substitution comprising as a plasma expander a recombinant gelatin-like protein. Characteristic is that the gelatin-like protein essentially is free of hydroxyproline. This absence of hydroxyproline prevents the composition from gelling and thus allows the use of high-molecular weight proteins in order to establish a suitable colloid osmotic pressure. Specific advantage of the gelatin-like proteins is that these avoid the risk of anaphylactic shock that exists in conjunction with the use of commercially available preparations.
Owner:FUJIFILM MFG EURO
Priming solutions for cardiopulmonary bypass
ActiveUS8969323B2Large volumeBiocideOrganic active ingredientsExtracorporeal circulationOncotic pressure
Owner:XVIVO PERFUSION
Process for preparing uniform molecule weight polymerized hemoglobin
InactiveCN1232533CEasy to separateOvercome the defect of inhomogeneityHaemoglobins/myoglobinsSolid phase adsorptionKilodalton
Owner:INST OF PROCESS ENG CHINESE ACAD OF SCI
A medium-term corneal preservation solution without serum components
The invention relates to cornea metaphase preserving fluid without a serum component. The cornea metaphase preserving fluid is prepared from an compound electrocular irrigating solution, sodium chloride, magnesium sulfate, monopotassium phosphate, chondroitin sulfate, sodium hyaluronate, a HEPES buffer solution, hydrochloric acid dexamethasone, reduced glutathione and levofloxacin. The cornea metaphase preserving fluid is reddish and transparent liquid with a specific electrolyte ionic concentration, a pH value, crystalloid osmotic pressure and colloid osmotic pressure. Needed raw materials are easy to get, the cornea metaphase preserving fluid does not contain the serum component, the risks of infecting special viruses is avoided, osmotic pressure of intracellular fluid and osmotic pressure of extracellular fluid are balanced through various ions, and the preservation effect is remarkable.
Owner:拜欧迪赛尔成都生物科技有限公司
An optimized antioxidant decellularized protection solution
The invention relates to an optimized anti-oxidative accelular protective solution, which has a critical effect on protection of structural completeness and biological nature of acellular tissues in the whole course of the decellularizing process. The protective solution is prepared from DMEM cellular culture medium L-histidine hydrochloride, allopurinol, chondroitin sulfate, low molecular dextran, hydroxypropyl methyl cellulose, HEPES buffer solution, dexamethason hydrochloride, reduced glutathione and levofloxacin. The protective solution is a light-red liquid with specific pH value, specific crystal and colloid osmotic pressure. The optimized anti-oxidative accelular protective solution is easily available in raw materials and economical in price, has strong applicability, wide application range and excellent anti-oxidation performance, and has a protective effect in the process of decellularizing biological tissues.
Owner:拜欧迪赛尔成都生物科技有限公司
A kind of preparation method of decellularized cornea
ActiveCN106421908BLow transparencyAvoid breedingTissue regenerationProsthesisCell-Extracellular MatrixECM Protein
The invention provides a method for preparing decellularized cornea. Due to the selection of components and proportions, colloid osmotic pressure of a decellularized cornea preparation liquid can be maintained by using a prepared protection liquid, and compared with a conventional decellularized cornea preparation liquid, the decellularized cornea preparation liquid is capable of remarkably alleviating the situation that the cornea transparency is degraded as an extracellular matrix such as collagen is excessively swelled and lost in the later cell treatment process; in addition, due to the addition of antibiotics such as tobramycin, bacterium propagation of susceptible cornea can be inhibited, and the contamination rate in the treatment process can be reduced. By adopting the method provided by the invention, cells can be crushed, and the situation that the trenchancy is degraded as cornea matrix collagen is damaged by long-term high pressure can be avoided. Secondly, as a detergent and nuclease act up simultaneously, cell debris and nucleic acid components can be relatively rapidly and effectively removed, and the situation that the trenchancy of the cornea is degraded as protein components such as cornea collagen are damaged in long-term treatment of the detergent and other components can be avoided.
Owner:SHENZHEN AINEAR CORNEA ENG
A kind of protective solution for acellular cornea preparation
ActiveCN106212442BLow transparencyAvoid breedingDead animal preservationCell-Extracellular MatrixAdditive ingredient
The invention provides a protection solution for preparing decellularized corneas. The protection solution is a PBS or HBSS buffer solution, wherein 5-12 g / L of hyaluronic acid, 5-20 g / L of chondroitin sulfate, and 3-10 g / L of low molecular weight dextran are added in the PBS or HBSS buffer solution. According to the protection solution, protective ingredients are added in the basic buffer solution, the prepared protection solution can maintain the colloid osmotic pressure of a preparing solution of decellularized corneas through selection of components and a proportion, and compared with a traditional preparing solution for decellularized corneas, cornea transparency decreasing caused by excessive swelling and missing of extracellular matrix ingredients such as collagen in the decellularization treatment process in a later stage can be remarkably relieved; besides, antibiotic ingredients such as tobramycin are added, breeding of bacteria such as pseudomonas aeruginosa, klebsiella biofilm, enterobacter and proteus which are likely to infect corneas is suppressed, and the contamination probability in the treatment process is avoided.
Owner:SHENZHEN AINEAR CORNEA ENG
Optical nanostructure probe and single cell colloid osmotic pressure detection platform and manufacturing method of optical nanostructure probe
ActiveCN109142180ARealize detectionReduce demandParticle size analysisPermeability/surface area analysisMicro-operationPhoton detection
The invention discloses an optical nanostructure probe, a single cell colloid osmotic pressure detection platform using the probe and a manufacturing method of the optical nanostructure probe, whereinthe detection platform comprises a sample cell, a microscopic device, an optical nanostructure probe, the optical nanostructure probe is fixed on a micro-operation device, the micro-operation deviceis connected with a control device, a light source device is connected with the control device, an output end for inputting a nano optical fiber and light inlet end for outputting the nano optical fiber of the optical nanostructure probe puncture into a sample cell in a micro pit, a light outlet end for outputting the nano optical fiber is connected with a photon detection device, and a data acquisition and analysis device converts the colloid osmotic pressure of the sample cell according to the photon intensity information at the light outlet end of the nanometer optical fiber. According to the invention, the detection of the living cells can be achieved, the influence of cell death and treatment on the real detection of the colloid osmotic pressure in the cell is avoided, and the reliability of measurement data is higher.
Owner:NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Drug combination targeting intracellular osmotic pressure for the treatment of cerebral edema
ActiveCN108653305BProtection from damageInhibits Stathmin activityNervous disorderBlood disorderNimodipineBULK ACTIVE INGREDIENT
A pharmaceutical composition for treating brain edema and a preparation method therefor. The active ingredients of the compound pharmaceutical composition include sennoside A, cantharidin or a derivative thereof, nimodipine or nifedipine, cinepazide maleate and edaravone. Cellular experiments are used to find active drugs and combinations thereof that can reduce colloidal osmotic pressure and crystal osmotic pressure in brain cells to treat brain edema and provide new pharmaceutical use in clinical applications.
Owner:NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com